Template:Ceftazidime: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 20: | Line 20: | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime overdosage|Overdosage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime overdosage|Overdosage]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime dosage and administration|Dosage and Administration]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime compatibility and stability|Compatibility and stability]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime how supplied|How Supplied]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime how supplied|How Supplied]] | ||
Revision as of 17:03, 30 December 2013
| Ceftazidime |
|---|
| FORATZ®,TAZICEF®,CEFTAZIDIME® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Overdosage |
| Dosage and Administration |
| Compatibility and stability |
| How Supplied |
| Labels and Packages |